Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Type to search articles, cases, and authors. Press ↵ to view all results. The Supreme Court has taken a lot of heat in recent months over the high rate at which it has sided with the Trump ...

We'll also see how well it generates new data, and finally we'll go over the key limitations of the copilot function. At the very end, I'll show you an alternative function to the copilot formula in ...

Executive function describes a set of cognitive processes and mental skills that help an individual plan, monitor, and successfully execute their goals. The “executive functions,” as they’re known, ...

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX +5.07%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Attorney General Pam Bondi pledges to go after "hate speech," saying there's no place for it after Charlie Kirk’s assassination. But that isn't U.S. law under the First Amendment, and Kirk himself ...